search

Tenax Therapeutics Inc (TENX)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know
Sep 23, 2026

Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know

Wall Street analysts predict a significant upside of 121.4% for Tenax Therapeutics (TENX), with a mean price target of $34.71. This optimism is supported by a positive trend in earnings estimate revisions and the company's Zacks Rank #2 (Buy) rating. Despite the potential for inflated price targets, the agreement among analysts and positive earnings revisions suggest a strong near-term upside for the stock.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish
Director Declan Doogan Buys 53,000 Shares of Tenax Therapeutics Inc (TENX)
Sep 19, 2026

Director Declan Doogan Buys 53,000 Shares of Tenax Therapeutics Inc (TENX)

Declan Doogan, a Director at Tenax Therapeutics Inc (TENX), recently purchased 53,000 shares, increasing his total holdings to 55,274 shares. This transaction, executed at $1.92 per share, is seen as a strong vote of confidence, especially given that insiders have made 12 buys and 0 sells over the past year. The article suggests this insider activity, combined with GuruFocus's GF Value and guru ownership data, provides a bullish outlook for the clinical-stage biotechnology company.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish